3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan has been researched along with oxidopamine in 1 studies
| Studies (3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan) | Trials (3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan) | Recent Studies (post-2010) (3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan) | Studies (oxidopamine) | Trials (oxidopamine) | Recent Studies (post-2010) (oxidopamine) |
|---|---|---|---|---|---|
| 75 | 0 | 24 | 8,630 | 6 | 2,407 |
| Protein | Taxonomy | 3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan (IC50) | oxidopamine (IC50) |
|---|---|---|---|
| Glyceraldehyde-3-phosphate dehydrogenase | Homo sapiens (human) | 8 | |
| DNA repair protein RAD52 homolog | Homo sapiens (human) | 0.779 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Corrigan, F; Hassall, MM; Thornton, E; Vink, R | 1 |
1 other study(ies) available for 3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan and oxidopamine
| Article | Year |
|---|---|
The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Functional Laterality; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Time Factors; Tryptophan; Tyrosine 3-Monooxygenase | 2014 |